A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
Latest Information Update: 29 Jan 2026
At a glance
- Drugs HJ 004 02 (Primary)
- Indications Liver metastases; Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms HJ-004-02-101
Most Recent Events
- 29 Jan 2026 New trial record
- 25 Dec 2025 According to Jing Medicine Technology media release, the first subject has been enrolled at Shanghai East Hospital.